Appendix C

Presentations and Site Visits

FEBRUARY 12, 2015, WASHINGTON, DC

• Department of Energy-National Nuclear Security Administration Activities Related to Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium: Recommendations for This NAS [National Academy of Sciences] Study. Jeffrey Chamberlin, Director, Office of Conversion, Material Management and Minimization, Department of Energy (DOE)-National Nuclear Security Administration (NNSA); Rilla Hamilton, Mo-99 Program Director, Office of Conversion, Material Management and Minimization, DOE-NNSA
• U.S. Nuclear Industry Initiatives for the Development of Molybdenum-99 Production Methods Without Highly Enriched Uranium: Recommendations for This NAS Study. Michael Guastella, Council on Radionuclides and Radiopharmaceuticals
• International Efforts Related to Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium: Recommendations for This NAS Study. Kevin Charlton, Organisation for Economic Co-operation and Development, Nuclear Energy Agency
• Production of Molybdenum-99 Without Highly Enriched Uranium: Perspectives from the Union of Concerned Scientists and Recommendations for This NAS Study. Ed Lyman, Union of Concerned Scientists

• Perspectives from Professional Societies and Recommendations for This NAS Study. Vasken Dilsizian, American Society of Nuclear Cardiology; Sue Bunning, Society of Nuclear Medicine and Molecular Imaging; Jeffrey Norenberg, National Association of Nuclear Pharmacies

MAY 11-13, 2015, BURR RIDGE, ILLINOIS

• Mallinckrodt Pharmaceuticals. Roy Brown, Senior Director, Strategic Alliances, Mallinckrodt Pharmaceuticals
• NorthStar Medical Technologies. James Harvey, Senior VP and Chief Science Officer, NorthStar Medical Radioisotopes LLC
• SHINE Medical Technologies. Gregory Piefer, Chief Executive Officer, SHINE Medical Technologies, Inc.
• Oak Ridge National Laboratory. Chris Bryan, Irradiations Manager, High Flux Isotope Reactor, Oak Ridge National Laboratory
• Argonne National Laboratory. Amanda Youker, Chemist, Nuclear Engineering Division; Sergey Chemerisov, Facility Manager of the Linac and Van de Graaff Accelerator Facility, Nuclear Engineering Division; Peter Tkac, Chemist, Nuclear Engineering Division
• Los Alamos National Laboratory. Greg Dale, Mo-99 Program Lead and R&D Engineer, Los Alamos National Laboratory
• Y-12 National Security Complex. John Creasy, Program Manager for Advanced Reactor & Materials Design, Y-12 National Security Complex
• Savannah River National Laboratory. James Klein, Advisory Engineer, Savannah River National Laboratory
• University of Missouri Research Reactor Center. Ralph Butler, Director, University of Missouri Research Reactor Center
• General Atomics. John Saurwein, Project Manager, Reactor-Based Mo-99 Production System Project, General Atomics
• Nordion, Tom Burnett, President, Medical Isotopes, Nordion

JUNE 2, 2015, CONFERENCE CALL

• Current and Future Trends of Utilization of Nuclear Cardiology Procedures and Competing Technologies. Dr. Marcelo Di Carli, Brigham and Women’s Hospital; Dr. Robert Gropler, Washington University School of Medicine in St Louis Raymond; Dr. Louise Thomson, Cedars-Sinai Los Angeles; Dr. William VanDecker, Temple University Hospital

JULY 22, 2015, CONFERENCE CALL

• IMV’s Methodology for the 2015 Nuclear Medicine Market Outlook Report. Gail Prochaska, Vice President, IMV Medical Information Division; Lorna Young, Senior Director, Market Research
• Experts Views on Mo-99 Current and Future Demand. Dr. Victor A. Ferrari, Penn Medicine; Dr. Linda D. Gillam, Atlantic Health System; Dr. Michael H. Picard, Massachusetts General Hospital

AUGUST 12-13, 2015, WASHINGTON, DC

• Uranium Lease and Take-Back Program. Peter Karcz, Office of Material Management and Minimization (NA-23), National Nuclear Security Administration; Hitesh Nigam, Office of Nuclear Materials Disposition (EM-22), Department of Energy, Office of Environmental Management
• FDA’s Role in Mo-99 Production and Utilization. Eric Duffy, Division Director, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration
• U.S. Nuclear Regulatory Commission Licensing Activities Related to Molybdenum-99 Production. Steven Lynch, Project Manager, Office of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission
• EU Observatory on the Supply of Medical Radioisotopes. Remigiusz Barańczyk, Head of Nuclear Fuel Market Observatory Sector, Euratom Supply Agency
• TechneLite^® Generators Manufactured with LEU-based Mo-99. Ira Goldman, Senior Director, Global Strategic Supply and Government Relations, Lantheus Medical Imaging
• Northwest Medical Isotopes Mo-99 Production Program. Carolyn Haass, Chief Operating Officer, Northwest Medical Isotope, LLC
• Tc-99m Payment Economics. Daniel Duvall, Medical Officer, Center for Medicare, Hospital and Ambulatory Policy Group, Centers for Medicare & Medicaid Services
• Economics of Global Radioisotope Production. Kevin Charlton, Senior Analyst, Nuclear Energy Agency, Organisation for Economic Co-operation and Development Supply Chain for Molybdenum-99 Generators. Scott Claunch, Director, Pharmacy Safety and Practice, Industry and Government Affairs, Cardinal Health Pharmacy

NOVEMBER 3, 2015, WASHINGTON, DC

• Uranium Lease and Take-Back Program—an Update. Peter Karcz, Office of Material Management and Minimization (NA-23), National Nuclear Security Administration; Theresa Kliczewski, Environmental specialist, Department of Energy, Office of Environmental Management
• U.S. Nuclear Regulatory Commission’s Role in Disposition of Radioactive Waste Resulting from Molybdenum-99 Production. Steven Lynch, Project Manager, Office of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission
• The Effect of Emissions from Fission-Based Medical Isotope Production on Nuclear Explosion Detection. Tim Evans, Office of Nuclear Verification (NA-243), NNSA; Ted Bowyer, Pacific Northwest National Laboratory
• Coquí’s Mo-99 Production Program. Carmen Irene Bigles, President & CEO, Coquí Radio Pharmaceuticals Corp.
• Niowave’s Mo-99 Production Program. Terry L. Grimm, President & Senior Scientist, Niowave, Inc.
• Perma-Fix Medical Mo-99 Production Program. Lou Centofanti, President and Chief Executive Officer, Perma-Fix
• UPPI’s LEU Walk. John Witkowski, President, United Pharmacy Partners

DECEMBER 16, 2015, OTTAWA, ONTARIO, CANADA

• NRCan’s Role in Establishing Policies and Programs for Securing Supply of Mo-99/Tc-99, and Other Radioisotopes in Canada. Daniel Brady, Deputy Director, Nuclear Science & Technology, Natural Resources Canada
• CIIC’s Project for Producing Tc-99m for Medical Use. Mark de Jong, Chief Technology Officer, Canadian Isotope Innovations Corp.; Kennedy Mang’era, Chief Operating Officer, Canadian Isotope Innovations Corp.; James George, Chief Executive Officer, Canadian Isotope Innovations Corp.
• PIPE’s Project for Producing Tc-99m for Medical Use. Chris Saunders, Prairie Isotope Production Enterprise; Sandor Demeter, Section Head of Nuclear Medicine at the Health Sciences Centre, Winnipeg MB, Co-Director of the Winnipeg Great West Life Positron Emission Tomography program, Associate Professor with the Department of Radiology (primary) and Community Health Sciences

• TRIUMF’s Project for Producing Tc-99m for Medical Use. Ken Buckley, Project Manager; Technical Support: Targetry, TRIUMF
• ACSI’s Oroject for Producing Tc-99m Using Medium Energy, High Current Cyclotrons. Brigitte Guérin, Full Professor, Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke; Alex Zyuzin, Director Research and Business Development, Advanced Cyclotron Systems, Inc. (ACSI)

MARCH 30, 2016, CONFERENCE CALL

• Uranium Lease and Take-Back Program—an Update. Peter Karcz, Office of Material Management and Minimization, National Nuclear Security Administration; Hitesh Nigam, Office of Nuclear Materials Disposition, Department of Energy, Office of Environmental Management; Theresa Kliczewski, Environmental specialist, Department of Energy, Office of Environmental Management; John Myers, DOE/EM

APRIL 20, 2016, WASHINGTON, DC

• Department of Energy-National Nuclear Security Administration: Closing Remarks and Suggestions Related to the Academies Study. Jeffrey Chamberlin, Director, Office of Conversion, Material Management and Minimization, Department of Energy (DOE)-National Nuclear Security Administration (NNSA); Rilla Hamilton, Mo-99 Program Director, Office of Conversion, Material Management and Minimization, DOE-NNSA

JULY 8, 2016, CONFERENCE CALL

• 2016 Medical Isotope Supply Review: 99Mo/99mTc Market Demand and Production Capacity Projection, 2016-2021. Kevin Charlton, Senior Analyst, Nuclear Energy Agency, OECD

SITE VISITS

• May 12, 2015: Argonne National Laboratory, Argonne, IL
• May 14, 2015: University of Missouri Research Reactor Center, Columbia, MO
• July 13-17, 2015: Russian Academy of Sciences, Moscow, Russia, and Russian Institute of Atomic Reactors Dimitrovgrad, Russia
• August 11, 2015: Cardinal Health Pharmacy, Beltsville, MD

• September 28-29, 2015: NTP Radioisotopes SOC, Ltd., and South African Fundamental Atomic Research Installation 1, Pretoria, South Africa
• October 19-22, 2015: CERCA, Paris, France; IRE, Fleurus, Belgium; Mallinckrodt and High Flux Reactor, Petten, the Netherlands
• December 14, 2015: Nordion, Kanata, Ontario, Canada
• December 15, 2015: Canadian Nuclear Laboratories, Chalk River, Ontario, Canada
• January 18-19, 2016: Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Heights, Australia
• February 4, 2016: Lantheus Medical Imaging, N. Billerica, MA